000303372 001__ 303372
000303372 005__ 20250810021955.0
000303372 0247_ $$2doi$$a10.1016/j.ejca.2025.115668
000303372 0247_ $$2pmid$$apmid:40749417
000303372 0247_ $$2ISSN$$a0959-8049
000303372 0247_ $$2ISSN$$a0014-2964
000303372 0247_ $$2ISSN$$a1879-0852
000303372 0247_ $$2ISSN$$a(1990)
000303372 0247_ $$2ISSN$$a1879-2995
000303372 0247_ $$2ISSN$$a(1965)
000303372 0247_ $$2altmetric$$aaltmetric:179745215
000303372 037__ $$aDKFZ-2025-01621
000303372 041__ $$aEnglish
000303372 082__ $$a610
000303372 1001_ $$aLeven, Anna-Sophia$$b0
000303372 245__ $$aSex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG.
000303372 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000303372 3367_ $$2DRIVER$$aarticle
000303372 3367_ $$2DataCite$$aOutput Types/Journal article
000303372 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754393783_8548
000303372 3367_ $$2BibTeX$$aARTICLE
000303372 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303372 3367_ $$00$$2EndNote$$aJournal Article
000303372 520__ $$aFemales and males differ in their innate and acquired immune responses. Thus, it is hypothesized that the efficacy of anti-tumor immunotherapies may differ by sex. This study aimed to investigate sex-specific survival differences upon different therapy types in metastatic melanoma.Patients with unresectable metastatic melanoma (stage IV, AJCCv8) of the skin or unknown primary, who had received first-line PD-1-based immune checkpoint inhibition (ICI) or BRAF/MEK-directed targeted therapy (TT) were identified from the prospective multicenter DeCOG skin cancer registry ADOREG. Study endpoints were progression-free survival (PFS) and overall survival (OS).A total of 2032 patients, 1274 males (62.7 %) and 758 females (37.3 %), received ICI (n = 1484) or TT (n = 548) between May 2010 and December 2020. At median follow-up of 28.6 months, no significant sex-specific differences in survival could be detected, neither in the total cohort nor by treatment type: PFS (total, p = 0.86; ICI, p = 0.46; TT, p = 0.21), OS (total, p = 0.60; ICI, p = 0.20; TT, p = 0.30). Multivariable Cox regression analyses also did not show a relevant prognostic influence by sex. Subgroup analyses were performed according to ICI therapy type. In n = 872 patients treated with PD-1 monotherapy, a survival advantage (PFS, p = 0.041; OS, p = 0.07) could be detected for males by univariable and multivariable analyses, whereas no sex-specific survival differences were found for n = 456 patients who received combination immunotherapy.No overall sex-specific survival differences were detected for metastatic melanoma patients in the first-line therapy setting. According to subgroup analyses males show a trend towards a survival advantage over females.
000303372 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000303372 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303372 650_7 $$2Other$$aImmune checkpoint inhibition therapy
000303372 650_7 $$2Other$$aMelanoma
000303372 650_7 $$2Other$$aSex
000303372 650_7 $$2Other$$aSurvival
000303372 650_7 $$2Other$$aTargeted therapy
000303372 7001_ $$aPeters, Triinu$$b1
000303372 7001_ $$aRajcsanyi, Luisa Sophie$$b2
000303372 7001_ $$aWeichenthal, Michael$$b3
000303372 7001_ $$aMohr, Peter$$b4
000303372 7001_ $$aMeier, Friedegund$$b5
000303372 7001_ $$avon Wasielewski, Imke$$b6
000303372 7001_ $$aGutzmer, Ralf$$b7
000303372 7001_ $$aUtikal, Jochen$$b8
000303372 7001_ $$aTerheyden, Patrick$$b9
000303372 7001_ $$aHerbst, Rudolf$$b10
000303372 7001_ $$aHaferkamp, Sebastian$$b11
000303372 7001_ $$aPföhler, Claudia$$b12
000303372 7001_ $$aLeiter, Ulrike$$b13
000303372 7001_ $$aForschner, Andrea$$b14
000303372 7001_ $$aKreuter, Alexander$$b15
000303372 7001_ $$aGebhardt, Christoffer$$b16
000303372 7001_ $$aLutze, Stine$$b17
000303372 7001_ $$aWeishaupt, Carsten$$b18
000303372 7001_ $$aGrabbe, Stephan$$b19
000303372 7001_ $$aDebus, Dirk$$b20
000303372 7001_ $$aHassel, Jessica$$b21
000303372 7001_ $$aWelzel, Julia$$b22
000303372 7001_ $$aHeinzerling, Lucie$$b23
000303372 7001_ $$aBerking, Carola$$b24
000303372 7001_ $$aLoquai, Carmen$$b25
000303372 7001_ $$aGambichler, Thilo$$b26
000303372 7001_ $$aZiemer, Mirjana$$b27
000303372 7001_ $$0P:(DE-He78)7bf2f090fe39a6cd6f0bccf5ea2d4fb3$$aBecker, Jürgen$$b28$$udkfz
000303372 7001_ $$0P:(DE-HGF)0$$aTasdogan, Alpaslan$$b29
000303372 7001_ $$0P:(DE-HGF)0$$aZimmer, Lisa$$b30
000303372 7001_ $$0P:(DE-HGF)0$$aLivingstone, Elisabeth$$b31
000303372 7001_ $$0P:(DE-HGF)0$$aSchadendorf, Dirk$$b32
000303372 7001_ $$0P:(DE-HGF)0$$aRoesch, Alexander$$b33
000303372 7001_ $$aHinney, Anke$$b34
000303372 7001_ $$aUgurel, Selma$$b35
000303372 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2025.115668$$gVol. 227, p. 115668 -$$p115668$$tEuropean journal of cancer$$v227$$x0959-8049$$y2025
000303372 909CO $$ooai:inrepo02.dkfz.de:303372$$pVDB
000303372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7bf2f090fe39a6cd6f0bccf5ea2d4fb3$$aDeutsches Krebsforschungszentrum$$b28$$kDKFZ
000303372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b29$$kDKFZ
000303372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000303372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b31$$kDKFZ
000303372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b32$$kDKFZ
000303372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000303372 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000303372 9141_ $$y2025
000303372 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-18$$wger
000303372 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2022$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000303372 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2022$$d2024-12-18
000303372 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000303372 980__ $$ajournal
000303372 980__ $$aVDB
000303372 980__ $$aI:(DE-He78)ED01-20160331
000303372 980__ $$aUNRESTRICTED